Calcium Electroporation for Basal Cell Carcinomas - Proof of Concept Study

Status

UNKNOWN

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05046262

Enrollment

Registered

2021-09-16

Start date

2020-01-08

Completion date

2022-02-22

Last updated

2021-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Basal Cell Carcinoma

Brief summary

25 patients with primary low-risk basal cell carcinoma treated with calcium electroporation

Detailed description

25 patients with primary low-risk basal cell carcinoma treated with calcium electroporation, if partial or no response after 3 months the treatment was repeated. Follow-up 3 and 12 months after last treatment.

Interventions

DRUGCalcium chloride

Calcium electroporation

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

Primary low risk basal cell carcinoma less than 3 cm in diameter \-

Exclusion criteria

Immunosuppression or organ transplant recipients Pregnancy or breastfeeding Allergy to local anesthetics

Design outcomes

Primary

Measure	Time frame
complete response	3 months

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026